* Pharmos Corp., of Alachua, Fla., said results werepresented showing the neuroprotective activity of the HU-211 in rats subjected to temporary focal forebrainischemia. The neurological outcome of the ischemia wassignificantly improved in the drug group compared tovehicle. The drug already has completed Phase I studiesin humans.

* ProCyte Corp., of Kirkland, Wash., began a Phase IIrandomized, evaluator-blinded, vehicle-controlled trial ofPC1358, a peptide-copper compound called Tricomin, formale pattern baldness.

* Sonus Pharmaceuticals Inc., of Bothell, Wash., saidunderwriters of its initial public offering (IPO) exercisedtheir option to purchase 427,500 shares of stock, half ofwhich were sold by selling shareholders. The companysold 2.85 million shares at $7 each in the IPO.

* SunPharm Corp., of Jacksonville, Fla., signed a licenseagreement with the University of Florida ResearchFoundation Inc., of Gainesville, for rights to a process formaking the iron chelator drug, desferrioxamine.

* Synsorb Biotech Corp., of Calgary, Alberta, wasgranted orphan drug status from the FDA for its product,Synsorb Pk, to treat Escherichia coli infections.

* Zynaxis Inc., of Malvern, Pa., and ALK A/S, ofHorsholm, Denmark, entered into a development andlicensing agreement that gives ALK exclusive rights toevaluate and develop Zynaxis' technologies for deliveryof bioactive substances in the area of allergies. Zynaxiswill get $1 million and research support.

(c) 1997 American Health Consultants. All rights reserved.